Pitch Deck: SAMANSIC Protocol Pilot Project

High-Output Healthspan Extension Initiative

​

1. Executive Summary

• Project Title: SAMANSIC Protocol Pilot Project - Healthspan Extension

• Innovator: Muayad S. Dawood Al-Samaraee

• Total Estimated Budget: $28,560,000 (maximum request with 20% contingency)

• Project Duration: 36 months (3 years)

• Funding Structure: Phased investment aligned with milestone achievement

• The Opportunity: The project addresses a $100B+ longevity market through a proprietary SUMOylation mechanism, with first-mover advantage in healthspan extension. The protocol delivers a 4.205x healthspan improvement factor with 76.2% morbidity compression, translating to 208.3 years of extended healthy years with 3,094% DNA repair enhancement.

• Investment Value Proposition: The scalable water infrastructure business model provides strong humanitarian and societal impact with first-mover advantage in healthspan extension.

​​

2. The Problem: The Crisis of Premature Aging

• Humanity faces a fundamental biological crisis. The maximum historical human lifespan of 122 years represents an empirical observation, not an absolute biological limit. Yet most individuals die from preventable causes - genetic vulnerabilities, chronic diseases, malnutrition, and nutritional deficiencies long before reaching their biological potential.

• The Human Cost: Those who served their nations through military or government service lose precious years that can never be recovered. An average life expectancy of 65 years is simply insufficient to achieve human aspirations in this exceptional era.

• The Scientific Reality: Current approaches to survival focus on escape - creating off-world habitats or underwater environments that attempt to recreate Earth's biosphere. These approaches are astronomically complex, potentially catastrophic, and unattainable for the vast majority of humanity.

• The Alternative: Rather than escaping Earth, we can transform human biology itself, enhancing the adaptive capacity that has allowed our species to survive in diverse environments for millennia.

​

3. The Solution: SAMANSIC Protocol

The SAMANSIC Protocol represents a paradigm shift in human survival strategy, moving away from high-risk technological approaches toward a biology-based solution that optimizes human resilience within existing environments.

​

3.1 The Gut-Brain-SUMO Axis

• The protocol operates through the gut-brain-SUMO axis, where nutritional supplements subjected to centrifugal forces simulating microgravity undergo physical transformation - modified crystal structures, altered hydration shells, and enhanced surface oxidation.

• Upon ingestion, these modified supplements produce a controlled gastric signal interpreted by the brainstem as a metabolic threat, stimulating vagus nerve activation and systemic SUMO protein upregulation. SUMO proteins are well-documented stress-inducible modifiers that stabilize nuclear and mitochondrial proteins, reduce apoptosis, and enhance cellular resilience.

​

Key Mechanisms:

• Enhanced DNA repair capacity by 3,094%

• Reduced oxidative stress by 55.0%

• Improved mitochondrial function with 67.2% ATP production increase

• Optimized mitochondrial dynamics with 154.1% fusion-fission balance improvement

• 96.9% reduction in mutation accumulation

​

3.2 The Four Pillars Protocol

• Magnesium: Co-factor for SUMO-activating enzymes, essential for over 300 enzymatic reactions, critical for DNA repair and mitochondrial function.

• N-Acetylcysteine: Glutathione precursor, reduces oxidative stress by 55.0%, supports the cell's primary antioxidant defense system.

• Alpha-Ketoglutarate: Enhances mitochondrial fusion, improves fusion-fission balance by 154.1%, supports the mitochondrial unfolded protein response.

• B-Complex Vitamins: Support NAD+ production and vascular endothelial function, ensuring metabolic cofactors for energy production and vascular health.

​

3.3 Compatible Water: The Environmental Anchor

The third key innovation, Compatible Water, provides three distinct forms of compatibility:

• Spatial Compatibility: Mineral composition precisely matched to the individual's geological location, achieving a compatibility index of 0.92.

• Structural Resistance: Protection against electromagnetic field-induced water dissociation, enhancing water structural integrity by 38.3%.

• Situational Compatibility: Dynamic mineral profile adjustment based on temperature, humidity, altitude, and seasonal changes using the mathematical relationship: M_opt(t) = M_baseline + ΔM(T, H, A, S).

​

3.4 Artificial Microgravity Generation

• The project requires the development of a first mass production prototype for Artificial Microgravity Generating Machines based on an advanced semi-centrifugal process concept, estimated at $7-9 million USD.

• This represents a strategic investment that positions the project between affordable laboratory simulators and multi-million dollar infrastructure of national space agencies, creating a unique and critical capability for the SAMANSIC protocol's development. Developing a proprietary prototype creates valuable intellectual property and establishes a unique technical capability.

• Building a robust ground-based prototype is a strategic hedge against the staggering costs of space-based experiments. Launching a single kilogram of material to space costs approximately $80,000, excluding experimental development. A system that can reliably simulate microgravity on Earth eliminates this recurring expense.

​

4. The Team: Structure and Expertise

​

4.1 Strategic Leadership

• Principal Innovator (Muayad S. Dawood Al-Samaraee): Visionary and theoretical framework holder, responsible for overseeing translation of the theoretical protocol into implementation steps, ensuring adherence to mathematical foundations (saturation-removal model), and communicating with the global scientific community.

• Project Executive Director: Administrative figure with experience in managing high-risk research projects, responsible for leading the executive team, managing resources and timelines, and ensuring achievement of key milestones in clinical phases.

​

4.2 Scientific and Advisory Committee

• Molecular Biology Expert (SUMO and DNA Repair): Designs protocols to measure the protocol's effect on SUMO protein activation, DNA repair capacity, and mutation accumulation using Western blotting and immunohistochemistry.

• Nutrition and Biochemistry Expert (Supplements and Mitochondria): Oversees preparation of nutritional supplements processed in microgravity-simulated environment using centrifuges, analyzing their effect on ATP production and oxidative stress, ensuring safe dosages.

• Water and Materials Physics Expert (Compatible Water): Develops production standards for "compatible water" based on the mathematical relationship C_opt = f(G_geology, M_groundwater, E_environment), develops rapid analysis devices to assess spatial and situational compatibility.

• Clinical Research Physician (Human Trials): Designs and manages clinical trials across Phases I-III, monitors safety, records adverse events, measures biomarkers of aging such as telomere length and epigenetic clocks.

​

4.3 Technical and Operational Development Team

• Systems Engineer (Water Infrastructure): Integrates compatible water production technology with existing infrastructures as outlined in the Omega Protocol.

• Data Analyst and Mathematical Modeling Specialist: Operates the saturation-removal model to monitor progress, calculates key performance indicators such as healthspan improvement and morbidity compression, updates models based on incoming data.

​

4.4 Governance, Ethics, and Equity Team

• Ethics and Compliance Officer: Ensures all trials adhere to global ethical standards, addresses issues of equity and accessibility, oversees the informed consent process for trial participants.

• Communications and Partnerships Officer: Builds bridges of collaboration with academic institutions, biotechnology companies, government entities, and space agencies, transparently disseminates project results.

​

5. Three-Phase Implementation Plan

Phase I: Preparation and Laboratory Validation (Months 0-12)

Funding Request: $2.5M - $3.0M

​

Key Activities:

• Complete formation of scientific and advisory committee

• Initiate collaboration with reputable research institutions for laboratory infrastructure

• Produce experimental batches of nutritional supplements in microgravity-simulated environment

• Develop prototype for compatible water production

• Launch scientific collaboration call to attract partners for independent validation

Key Deliverables:

• Formation of advisory committee

• Supplement and compatible water prototypes

• Preliminary SUMO biomarker data

• IND/CTA submission

Budget Allocation:

• Personnel & Salaries: $850,000

• Laboratory & Clinical Operations: $1,100,000

• Infrastructure & Equipment: $650,000

• Artificial Microgravity Prototype: $7,000,000

• Regulatory & Compliance: $200,000

• Travel & Communications: $100,000

• Contingency (20%): $1,980,000

 

Phase II: Pilot Clinical Trials (Months 13-36)

Funding Request: $5.0M - $6.0M

​

Key Activities:

• Phase I/II trials on limited group of volunteers to measure safety and protocol tolerance

• Confirm effects on biomarkers (SUMO protein, telomere length)

• Use saturation-removal model to evaluate data and continuously adjust dosages

Key Deliverables:

• Phase I safety study completion

• Phase IIa biomarker validation

• Telomere and epigenetic data

• DSMB review

Budget Allocation:

• Personnel & Salaries: $1,400,000

• Laboratory & Clinical Operations: $4,500,000

• Infrastructure & Equipment: $350,000

• Artificial Microgravity Prototype: $1,000,000

• Regulatory & Compliance: $150,000

• Travel & Communications: $150,000

• Contingency (20%): $1,510,000

 

Phase III: Scaling and Knowledge Transfer (Months 36+)

Funding Request: $4.0M - $6.0M

​

Key Activities:

• Apply Omega Protocol to establish sovereign infrastructure for compatible water production

• Initiate Phase III trials on broader scale to evaluate healthspan and morbidity compression

• Collaborate with public health agencies and defense ministries

Key Deliverables:

• Phase IIb efficacy data

• Phase III trial initiation

• Omega Protocol implementation roadmap

• Regulatory pathway clarity

Budget Allocation:

• Personnel & Salaries: $1,200,000

• Laboratory & Clinical Operations: $3,800,000

• Infrastructure & Equipment: $100,000

• Artificial Microgravity Prototype: $1,000,000

• Regulatory & Compliance: $100,000

• Travel & Communications: $150,000

• Contingency (20%): $1,270,000

 

6. Comprehensive Budget Breakdown

​

6.1 Personnel and Salaries ($3.45M over 3 years)

• Project Executive Director oversees project management and team coordination, with annual compensation ranging from $150,000 to $180,000, totaling $450,000 to $540,000 over three years.

• Principal Innovator (Muayad S. Dawood Al-Samaraee) provides scientific oversight and global engagement, with annual compensation from $120,000 to $150,000, totaling $360,000 to $450,000 over three years.

• Molecular Biologist (SUMO/DNA Repair) conducts lab validation and biomarker measurement, with annual compensation from $100,000 to $130,000, totaling $300,000 to $390,000.

• Nutrition and Biochemistry Expert oversees supplement preparation and mitochondrial analysis, with annual compensation from $90,000 to $120,000, totaling $270,000 to $360,000.

• Water and Materials Physicist develops compatible water standards and rapid analysis tools, with annual compensation from $90,000 to $120,000, totaling $270,000 to $360,000.

• Clinical Research Physician designs trials, monitors safety, and records adverse events, with annual compensation from $180,000 to $220,000, totaling $540,000 to $660,000.

• Systems Engineer (Water Infrastructure) integrates the Omega Protocol, with annual compensation from $85,000 to $110,000, totaling $255,000 to $330,000.

• Data Analyst and Mathematical Modeler operates the saturation-removal model and tracks KPIs, with annual compensation from $75,000 to $95,000, totaling $225,000 to $285,000.

• Ethics and Compliance Officer oversees ethical review and informed consent processes, with annual compensation from $70,000 to $90,000, totaling $210,000 to $270,000.

• Communications and Partnerships Officer manages stakeholder engagement and dissemination, with annual compensation from $65,000 to $85,000, totaling $195,000 to $255,000.

• Research Technicians (2-3 FTE) provide lab support and sample processing, with each earning $50,000 to $65,000 annually, totaling $300,000 to $585,000.

• Administrative Support handles general operations and logistics, with annual compensation from $40,000 to $55,000, totaling $120,000 to $165,000.

• Fully burdened rates include benefits estimated at 25-35% of base salaries.

​

6.2 Laboratory and Clinical Operations ($9.4M over 3 years)

​

Phase I: Preclinical and Laboratory Validation (Year 1) - $1.1M

• Laboratory Setup and Rental covers lab space lease and infrastructure for 12 months, estimated at $150,000 to $250,000.

• Cell Culture and Animal Models supports preclinical model development for SUMOylation validation, estimated at $200,000 to $300,000.

• Reagents and Consumables includes enzymes, antibodies, sequencing reagents, PCR, and Western blotting supplies, estimated at $150,000 to $250,000.

• Supplement Prototype Production covers development of microgravity-simulated supplement processing, estimated at $100,000 to $200,000.

• Compatible Water Prototype supports development of a prototype for water optimization per formula, estimated at $100,000 to $150,000.

• Quality Control Systems implements GLP standards and initial analytical validation, estimated at $200,000 to $300,000.

​

Phase II: Clinical Trials (Years 2-3) - $4.5M

• Phase I Trial (Safety) involves 20-50 healthy volunteers over 6-12 months, estimated at $500,000 to $1,500,000.

• Phase IIa Trial (Biomarker) includes 50-100 subjects for biomarker endpoints (SUMO, telomere, epigenetic), estimated at $1,000,000 to $3,000,000.

• Phase IIb Trial (Efficacy) involves 100-300 subjects with extended biomarker measurement, estimated at $1,500,000 to $3,000,000.

• Clinical Site Costs cover site start-up, institutional fees, and principal investigator grants, estimated at $400,000 to $800,000.

• Patient Recruitment and Retention funds recruitment campaigns and patient reimbursements, estimated at $300,000 to $700,000.

• Clinical Supplies and Kits includes study drug (supplements) and placebo manufacturing, estimated at $200,000 to $400,000.

• Central Laboratory Costs covers biomarker analysis including telomere length and epigenetic clocks, estimated at $300,000 to $600,000.

• Monitoring and Data Management includes CRO monitoring, data entry, and query resolution, estimated at $300,000 to $500,000.

​

Phase III: Scaling and Pivotal Trials (Year 3+) - $3.8M

• Phase III Trial Preparation covers protocol design, regulatory submission, and site selection, estimated at $400,000 to $600,000.

• Phase III Trial (Pivotal) involves 500-1,500 subjects across multiple centers over 12-24 months, estimated at $2,000,000 to $5,000,000.

• Expanded Clinical Sites establishes 5-10 sites across multiple regions, estimated at $500,000 to $1,000,000.

• Sample Collection and Biobanking enables long-term biospecimen storage for future analysis, estimated at $300,000 to $500,000.

• Statistical Analysis and Reporting covers final database lock and statistician fees, estimated at $400,000 to $600,000.

​

6.3 Infrastructure and Equipment ($1.1M over 3 years)

• Biosafety Cabinets and Fume Hoods provide laboratory safety equipment, estimated at $50,000 to $80,000.

• PCR and qPCR Systems support molecular biology work, estimated at $60,000 to $100,000.

• Centrifuge Systems enable microgravity simulation, estimated at $50,000 to $150,000.

• Spectroscopy and Imaging includes high-resolution microscopy and molecular imaging, estimated at $100,000 to $200,000.

• Water Processing Equipment establishes a compatible water production system at pilot scale, estimated at $150,000 to $250,000.

• Laboratory Information Management System (LIMS) manages sample tracking and data, estimated at $50,000 to $100,000.

• Data Storage and Servers includes secure cloud and on-site storage, estimated at $50,000 to $80,000.

• Electronic Lab Notebooks enable GLP-compliant documentation, estimated at $30,000 to $50,000.

• Equipment costs may be lower if partnerships with existing research institutions are established. Personnel costs typically account for about 44% of total R&D project costs, with equipment at approximately 20%.

​

6.4 Artificial Microgravity Prototype ($7-9M)

This strategic investment represents a significant portion of the budget and includes design and assembly of a first mass production prototype based on an advanced semi-centrifugal process concept.

Scope includes:

• Advanced semi-centrifugal process concept development

• Control software and sample handling modules

• Environmental chambers for integrated production system

• Testing and validation protocols

Strategic Value:

• Creates valuable intellectual property

• Establishes unique technical capability

• Eliminates recurring space-based experiment costs ($80,000/kg launch cost avoided)

• Positions project between affordable laboratory simulators and national space agency infrastructure

 

6.5 Regulatory and Compliance ($0.45M over 3 years)

• Health Authority Fees cover FDA, EMA, or local equivalent submissions, estimated at $75,000 to $150,000.

• Ethics Committee Approvals support IRB/EC submissions across multiple sites, estimated at $50,000 to $100,000.

• Regulatory Affairs Consultants provide expertise for IND/CTA submission preparation, estimated at $100,000 to $200,000.

• Legal and Intellectual Property covers patent filings and confidentiality agreements, estimated at $75,000 to $150,000.

• Good Clinical Practice (GCP) Training delivers investigator training programs, estimated at $25,000 to $50,000.

• Safety Monitoring Board (DSMB) provides independent monitoring of trial safety, estimated at $25,000 to $50,000.

​

6.6 Travel and Communications ($0.4M over 3 years)

• Global Scientific Meetings enable attendance at ICGEB and biotech conferences for networking, estimated at $60,000 to $100,000.

• Site Visits support monitoring visits to clinical sites, estimated at $50,000 to $100,000.

• International Collaborations enable visits to partner institutions, estimated at $40,000 to $80,000.

• Workshops and Training deliver staff and investigator training events, estimated at $30,000 to $60,000.

• Publications and Dissemination cover open-access fees and conference presentations, estimated at $50,000 to $80,000.

• Communications and Marketing includes project website and stakeholder outreach, estimated at $30,000 to $60,000.

​

6.7 Budget Summary by Phase

• Phase I Total: $11,880,000

• Phase II Total: $9,060,000

• Phase III Total: $7,620,000

• Grand Total (with 20% contingency): $28,560,000

​

7. Key Cost Drivers and Assumptions

• Scientific Foundation: The protocol is based on well-documented biological mechanisms and the gut-brain-SUMO axis, with quantifiable mathematical models that are testable, providing high scientific value.

• Scalability: Through the Omega Protocol, the project presents a practical model that can be scaled through water infrastructure, ensuring long-term investment returns.

• Ecosystem Compatibility: This compatibility provides a fertile environment for project growth, leveraging the legislative framework supporting innovation, local funding programs, and investor networks.

​

Industry Benchmark Costs:

• For biologic (complex) development, preclinical costs range from $5.4M to $16.2M, Phase 1 from $1.9M to $3.0M, Phase 2 from $4.5M to $10.5M, and Phase 3 from $27.7M to $80.5M.

• For diagnostic assay development, preclinical ranges from $1.0M to $5.0M, Phase 1 from $1.0M to $3.0M, and Phase 2 from $1.0M to $6.0M.

• Probability of Success (Industry Averages):

• Preclinical success rates range from 41% to 65%. Phase 1 ranges from 50% to 68%. Phase 2 ranges from 19% to 46%. Phase 3 ranges from 40% to 71%.

​

8. Risk Mitigation and Contingency

• Clinical trial recruitment delays are mitigated with a 15-20% buffer through multi-site strategy and patient advocacy partnerships.

• CRO scope creep is mitigated with a 15-20% buffer through detailed SOW agreements.

• Regulatory setbacks are mitigated with a 10-15% buffer through regulatory consultants and pre-IND meetings.

• Personnel attrition is mitigated with a 5-10% buffer through competitive compensation and equity options.

• Scientific setbacks are mitigated with a 10-15% buffer through parallel research tracks and adaptive trial design.

​

9. Partnership and Co-funding Opportunities

• Ecosystem Compatibility: The state providing care and financial support can benefit from the expertise of its innovation and entrepreneurship centers, such as incubators and accelerators specialized in biotechnology, which possess experience in incubating biotechnology projects and providing advisory services and logistical support.

• Institutional Partnerships: Institutions like ICGEB (International Centre for Genetic Engineering and Biotechnology) offer research grants up to €25,000 per year for collaborative research and support young scientists.

• Organizations such as ICGEB provide annual calls for research proposals in basic science, human health, industrial biotechnology, and bioenergy, supporting collaborative research projects with a maximum annual contribution of €25,000.

• Government and Military Partnerships: The project's ethical dimension of honoring service categories (military and government) opens doors for collaboration with public sectors, including defense ministries interested in enhancing soldier resilience and healthspan.

​

10. Investment Summary

 

Total Maximum Request: $28,560,000

​

Investment Value Proposition:

• The project addresses a $100B+ longevity market through a proprietary SUMOylation mechanism. The scalable water infrastructure business model provides strong humanitarian and societal impact with first-mover advantage in healthspan extension.

​

Key Performance Metrics:

• The protocol delivers a 4.205x healthspan improvement factor with 76.2% morbidity compression. This translates to 208.3 years of extended healthy years with 3,094% DNA repair enhancement. Additional metrics include 55.0% oxidative stress reduction, 67.2% ATP production increase, 96.9% mutation accumulation reduction, and 92.4% environmental stress reduction.

​

Strategic Asset Development:

• The $7-9 million investment in the artificial microgravity prototype creates valuable intellectual property and establishes unique technical capability that can be leveraged for future revenue streams through licensing of prototype technology, contract manufacturing services, research partnerships with space agencies and pharmaceutical companies, and development of proprietary supplements and water technologies.

​

11. Conclusion

• The formation of this team, according to the proposed structure, represents the first step toward transforming the ambition of the SAMANSIC Protocol into a tangible reality. The project represents an opportunity for global leadership in the field of healthspan extension, from a scientific and humanitarian standpoint, befitting the reputation of the sponsoring state as a center for innovation in the region.

• We reject the fate of premature death from interventions that were supposed to protect us, from diseases that could have been prevented, or from deficiencies that could have been corrected. The SAMANSIC Protocol is our path to claiming the full biological potential that evolution and innovation have made possible - a life of health, beauty, happiness, and wonder extended beyond all historical precedent, where death comes not from preventable causes but only after a life fully lived, fully experienced, and fully realized.

• This budget is a maximum estimate designed to cover the full scope of the pilot project. Actual costs may be reduced through strategic partnerships, in-kind contributions, and collaboration with academic and government institutions.

​

For further information, partnership inquiries, or to discuss funding opportunities: please contact the Innovator.

​